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Abstract
Introduction: In the search for biomarkers that allow the prediction of neonatal growth and development, placental growth hormone 
(PGH), pituitary growth hormone (GH1), insulin-like growth factor 1 (IGF-1), and ghrelin concentrations were assessed in the amniotic 
fluid and in the umbilical cord blood of 92 neonates.
Material and methods: The proteins were assayed by the ELISA method. Their concentration values were compared in 57 full-term 
neonates and 35 prematurely born neonates, as well as in both large (> 4,000 g) and small neonates (< 2,500 g). Also, body mass and 
placenta mass were compared.
Results: Statistically significant differences both between prematurely born neonates and full-term neonates and between large and 
small neonates were obtained only in terms of the body mass of neonates and placenta mass. The concentration values of the hormones 
studied did not show statistically significant differences. A distinct tendency was noticed towards an increase in PGH concentration in 
both prematurely born and small neonates. In large neonates, statistically significantly higher IGF-1 concentrations were found compared 
to the prematurely born neonates.
Conclusions: Our studies indicate an important role for PGH in maintaining a proper IGF-1 pool and demonstrate the existence of 
a direct influence on the function of the placenta in prematurely born neonates through the activation of compensation mechanisms, 
which stimulate IGF-1 synthesis. (Endokrynol Pol 2013; 64 (4): 293–298)
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Streszczenie
Wstęp: Poszukując czynników, które pozwoliłyby na prognozowanie dalszego rozwoju noworodka, oznaczano we krwi pępowinowej 
oraz w płynie owodniowym 92. noworodków stężenie łożyskowego hormonu wzrostu (PGH), przysadkowego hormonu wzrostu (GH1), 
insulinopodobnego czynnika wzrostu 1 (IGF-1) oraz greliny.
Materiał i metody: Omawiane białka były oznaczane metoda ELISA. Porównano wartości ich stężenia u 57. noworodków i 35. wcześniaków 
oraz u noworodków dużych (> 4000 g) i małych (< 2500 g). Porównano również masę ciała noworodków i masę łożyska.
Wyniki: Statystycznie znamienne różnice pomiędzy wcześniakami i noworodkami donoszonymi oraz między dużymi i małymi dziećmi 
uzyskano jedynie w odniesieniu do masy ciała noworodków i masy łożyska. Natomiast wartości stężeń badanych hormonów nie wyka-
zywały statystycznie znamiennych różnic. Zaobserwowano wyraźne tendencję wzrastania stężenia PGH u wcześniaków i noworodków 
małych. Natomiast u noworodków dużych uzyskano statystycznie znamienne wyższe stężenie IGF-1 w porównaniu z wcześniakami.
Wnioski: Badania nasze wskazują na ważną rolę PGH w utrzymaniu odpowiedniej puli IGF-1 oraz bezpośredni wpływ na funkcję łożyska u 
wcześniaków poprzez uruchomienie mechanizmów kompensacyjnych stymulujących syntezę IGF-1. (Endokrynol Pol 2013; 64 (4): 293–298)
Słowa kluczowe: PGH, GH1, IGF-1, grelina, noworodek, surowica krwi pępowinowej, płyn owodniowy
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Introduction
The proteins listed in the title belong to the group of 
growth and cell metabolism modulators. They are regu-
lated by complexes of factors that act in systemic and 
local systems that differ in the pre- and postnatal pe-
riods. Growth processes are relatively well recognised 
in the postnatal phase, where the key endocrine factor 
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controlling growth is the growth hormone 1/insulin-
like growth factor 1 (GH1/IGF-1) axis [1]. Considerably 
less is known about the mechanisms controlling growth 
in foetal life in which IGF-1 does not work in conjunc-
tion with GH1 [2, 3].
The placental growth hormone is a product of the 
GH-V gene; it is a member of a family of five growth hor-
mone genes located on the long arm of chromosome 17. 
This hormone has been known since 1985, when it was 
discovered by Hennen et al. [4, 5]. It shows a high level 
of homology to the pituitary growth hormone, being 
different in terms of 13 amino acids and N-glycosyla-
tion sites. This protein is synthesised and secreted by 
a syncytiotrophoblast and extravillous cytotrophoblast 
[2, 6, 7]. In their detailed review, Fuglsang and Ovesen 
[2] show that PGH seems to be only a maternal phe-
nomenon. There are some publications describing the 
presence of this protein both in umbilical cord blood 
serum and amniotic fluid [8–10].
The aim of this study is an assessment of the concen-
trations of the studied proteins in umbilical cord blood 
serum and amniotic fluid. In addition, the authors have 
tried to determine if there is any relationship between 
the results obtained with neonate body mass and 
placenta mass, and the search for factors which would 
allow a child’s development to be predicted.
Material and methods
Investigations were performed on umbilical cord blood 
and amniotic fluid samples. A total of 92 umbilical cord 
blood samples originating from one triplet pregnancy, 
12 twin pregnancies and 79 singleton pregnancies 
were collected. The majority of the pregnancies were 
normal, eight pregnant women had type I diabetes 
(six type G1, one G2, and one type C). Among the 
92 neonates, 52 boys and 40 girls were born. There were 
35 infants born prematurely between weeks 22 and 
37 of pregnancy, and 57 full-term neonates, born be-
tween weeks 37 and 42.
Among the neonates, 33 weighed more than 4,000 
g and 38 less than 2,500 g.
All the neonates were examined by a neonatologist 
and weighed after birth; placenta mass was also meas-
ured. In four of the twin pregnancies, the placentas 
were common.
In neonate blood and amniotic fluid samples, the 
following hormones were assayed: pituitary growth 
hormone (GH1), placental growth hormone (PGH), 
insulin-like growth factor 1 (IGF-1) and acylated ghrelin.
Most of the amniotic fluids originated from amnio-
centesis: four fluids from weeks 14 and 15 of pregnancy, 
four fluids from week 17, two fluids from weeks 19 
and 22, and two fluids collected during birth. A total of 
12 amniotic fluids were collected from healthy pregnant 
women. All the investigated proteins were assayed using 
the ELISA method. GH1 and IGF-1 were assayed with 
R&D Systems ELISA Kits (R&D Systems, Minneapolis, 
MN, USA), PGH protein with a Uscn life Science ELISA 
Kit (Uscn life Science, Wuhan, China) and ghrelin was as-
sayed with a BioVendor ELISA Kit (BioVendor, Modrice, 
Czech Republic), all according to the manufacturers’ pro-
tocols. Briefly, the samples and standards were added as 
duplicates to micro-titration plates coated with antibodies 
against the studied substance. After incubation and wash-
ing, a secondary antibody was added, and the sample 
was incubated again. After subsequent washing, a colour 
reaction substrate, catalysed by a conjugated enzyme, 
was added. The reaction was stopped with 2M sulphuric 
acid. The plates were read in an MRX reader (Dynex, 
Chantilly, VA, USA). For statistical analysis, SigmaStat 
3.5 software was used. The normality of the distribution of 
the variables was analysed with the Shapiro-Wilk method. 
For a comparison of the non-parametrical distributed 
variables, the Mann-Whitney Rank Sum Test was used; 
p < 0.05 was considered statistically significant.
Results
As per the results presented in Table I, the median value 
for all the investigated factors was higher in full-term 
neonates than in prematurely born infants, except for PGH 
concentration, whose value was higher in prematurely 
born infants. Statistically significant differences between 
the two groups were shown only for neonate body mass 
and placenta mass. Concentrations of the investigated 
hormones did not show statistically significant differences. 
The highest mean values in full-term and prematurely 
born neonates were observed in IGF-1 concentrations 
(87.5 ng/mL, 57.8 ng/mL) and in pituitary growth hormone 
concentrations (3,176.2 pg/mL, 2,886.5 pg/mL).
During the analysis of particular cases, special attention 
was paid to the distinct tendency of PGH concentration 
to increase in small neonates compared to larger ones.
A similar situation was observed in the case of 
ghrelin concentrations. In some premature infants, 
ghrelin concentrations were higher than 100 pg/mL, 
while in full-term neonates they were around 50 pg/mL. 
However, in both cases, no statistically significant dif-
ferences were observed. Besides, in five neonates (three 
prematurely born, two full-term infants), exceptionally 
low IGF-1 values, lower than 10 ng/mL, were observed, 
and this is within the error limits.
Additionally, large (> 4,000 g) and small (< 2,500 
g) neonates were compared. The results are presented 
in Table II.
As per the results from Table II, statistically signifi-
cant differences were shown for neonate body mass 
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and placenta mass. Higher IGF-1 concentrations in 
the blood serum of large neonates compared to small 
neonates was statistically significant. Moreover, as in 
Table I, higher PGH concentrations were recorded in 
small neonates than in large neonates.
The growth hormone concentration ratio was also 
evaluated: GH1/PGH, GH1/IGF-1, GH1/ghrelin, PGH/
IGF-1, PGH/ghrelin in the blood serum of full-term and 
prematurely born infants (Table III). In this table, the 
median of GH1 concentration in umbilical cord blood 
serum of full-term neonates was nine times higher than 
PGH, and six times higher than in prematurely born 
infants. The ratio of GH1 and IGF-1 concentrations in 
both investigated groups of neonates was similar and 
the IGF-1 concentration was about 25 times higher than 
GH1. The median IGF-1 concentration was 252 times 
higher than PGH in full-term neonates and 133 times 
higher in prematurely born infants. As for concentration 
ratio, there were no statistically significant differences 
between full-term and prematurely born neonates.
Similar to the results from Table 2, a significant cor-
relation in both investigated groups occurred between 
neonate body mass and placenta mass, and between 
GH1 and PGH in cord blood serum. Only full-term 
neonate body mass correlated with IGF-1 (Table IV).
Pituitary growth hormone concentration was the 
highest in second trimester amniotic fluid. PGH concen-
tration was 50% lower, and the lowest concentrations 
were those of IGF-1 and ghrelin, and these were within 
error limits (Table V). In the amniotic fluid collected 
during the delivery, both growth hormone concentra-
tions were several times lower than those for the second 
trimester of pregnancy.
Discussion
Our research showed that statistically significant dif-
ferences in full-term and prematurely born neonates 
occurred only for neonate body mass and placenta 
mass. Median hormone concentration values for GH1, 
IGF-1, and ghrelin did not show statistically significant 
differences, and these were higher in full-term neonates 
and in the group of large infants (> 4,000 g). This situa-
tion was different for PGH concentrations. The median 
Table I. Minimal values, maximal values, and median of the investigated hormones concentrations in umbilical cord blood 
of full-term and premature born neonates; neonate and placenta mass
Tabela I. Wartości minimalne, maksymalne, mediana stężeń badanych hormonów we krwi pępowinowej noworodków 
donoszonych i wcześniaków, masa ciała noworodków i łożyska
Investigated material Full-term neonate Prematurely born neonate p value
Min-max concentration Median Min-max concentration Median
GH1 [pg/mL] 937.8–8,131.6 3,176.2 882.2–13,358.3 2,886.5 0.946
PGH [pg/mL] 0–2,015.6 346.9 106.4–1,728.7 433.9 0.478
IGF I [ng/mL] 10–132.2 87.5 10–110.6 57.8 0.184
Ghrelin [pg/mL] 14.2–175.5 70.5 14.3–184.5 53.5 0.617
Neonate [g] 1,790–5,430 4,230 600–2,650 1,770 < 0.001
Placenta [g] 270–1,300 700 150–900 420 < 0.001
Table II. Minimal values, maximal values, and median of the investigated hormones concentrations in umbilical cord blood 
of large (> 4,000 g) and small (< 2,500 g) neonates
Tabela II. Wartości minimalne, maksymalne, mediana badanych hormonów we krwi pępowinowej noworodków dużych, 
powyżej 4000 g i małych poniżej 2500 g
Investigated material Neonate > 4,000 g Neonate < 2,500 g p value
Min-max concentration Median Min-max concentration Median
GH1 [pg/mL] 937.8–5,999.3 3,117.3 882.2–13,358.3 2,891.9 0.847
PGH [pg/mL] 0–2,015.6 344.3 106.4–1,768.6 396.6 0.386
IGF I [ng/mL] 45.4–132.2 98.9 10–110.6 50.0 < 0.001
ghrelin [pg/mL] 14.3–165.4 75.4 14.3–184.5 60.2 0.505
Neonate [g] 4,000–5,430 4,400 600–2,500 1,840 < 0.001
Placenta [g] 550–950 720 150–1,300 420 < 0.001
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Table IV. Correlations between neonate birth weight and placenta mass, and the investigated hormones in cord blood serum
Tabela IV. Korelacje pomiędzy masą ciała noworodków i masą łożyska oraz badanymi hormonami we krwi pępowinowej
Prematurely born infants r p n
Neonate birth weight and placenta mass 0.574 0.001 32
Placenta mass and GH1 0.447 0.0152 29
GH1 and PGH 0.388 0.0377 29
PGH and ghrelin 0.365 0.0517 29
PGH and IGF-1 –0.548 0.0325 15
Ghrelin and IGF-1 –0.57 0.0252 15
Full-term neonates r p n
Neonate birth weight and placenta mass 0.428 0.00255 48
Neonate birth weight and IGF-1 0.485 0.0141 25
GH1 and PGH 0.341 0.0179 48
Table III. Evaluation of the ratios of the investigated hormones from umbilical cord blood of full-term and prematurely born 
infants with median value. Hormone concentrations are presented in pg/mL
Tabela III. Ocena stosunku stężeń badanych hormonów z krwi pępowinowej noworodków donoszonych i wcześniaków z 
wykorzystaniem wartości mediany. Stężenia hormonów podano w [pg/mL]
Analysed hormones 
[pg/mL]
Full-term neonates Prematurely born neonates p value
Median Concentration ratio Median Concentration ratio
GH1/PGH 3,176.2/346.9 9:1 2,886.5/433.9 7:1 0.940
GH1/IGF-1 3,176.2/87,500 1:28 2,886.5/57,800 1:20 0.146
GH1/ghrelin 3,176.2/70.5 45:1 2,886.5/53.5 54:1 0.805
PGH/IGF-1 346.9/87,500 1:252 433.9/57,800 1:133 0.209
PGH/ghrelin 346.9/70.5 5:1 433.9/53.5 8:1 0.542
value of this hormone concentration was higher in 
prematurely born and small neonates (< 2,500 g), but 
the differences were not statistically significant (Table 
I and II). In the comparison of large and small infants 
(Table II), statistically significant differences also oc-
curred in IGF-1 concentration. The median value of 
this hormone concentration was higher in large neo-
nates. The placental growth hormone is synthesised by 
syncytiotrophoblast and secreted into the intervillous 
space. The presence of this hormone in the syncytio-
trophoblast was confirmed with immunohistochemical 
methods [6]. Besides, with molecular methods GH-V 
gene expression was shown in the placenta, and no 
expression of the GH-N gene, responsible for GH1 
production, was demonstrated [7, 11, 12]. Moreover, the 
presence of PGH receptors was detected in the placenta, 
and this suggests a direct influence of PGH on placenta 
function through auto- and paracrine mechanisms, 
Table V. Hormone concentration values in amniotic fluid
Tabela V. Wartości stężeń badanych hormonów w płynie owodniowym
Week of pregnancy GH1 [pg/mL] PGH [pg/mL] IGF-1 [ng/mL] Ghrelin [pg/mL]
14–15 8,000 4,610.3 28.2 8.3
17 8,000 4,814.7 27.4 8.4
19–22 8,000 1,699.9 26.2 11.8
Collected during delivery 1,446.2 600 26.6 6
297
Endokrynologia Polska 2013; 64 (4)
PR
A
C
E 
O
RY
G
IN
A
LN
E
which control the secretionary and proliferative activ-
ity of the placenta [13–15]. Higher PGH concentrations 
observed in prematurely born and small foetuses may 
indicate compensation mechanisms, in which elevated 
PGH secretion stimulates IGF-1 synthesis in placental 
tissue, which accelerates the proliferation and growth 
of placental tissue [6].
It seems that the foetal pituitary gland does not play 
an important role in those compensation processes. 
No GH-V gene expression was noted in the pituitary 
gland, and no GH-N gene transcript was detected in 
the placenta [2, 7, 11, 16, 17]. Furthermore, the median 
value of GH1 concentrations was similar in large and 
small neonates and also in full-term and prematurely 
born infants (Table I and II). By comparing concentra-
tions of the particular proteins, we showed that IGF-1 
concentration values in full-term neonates is 252 times 
higher compared to PGH, and in prematurely born 
infants only 133 times higher (Table III). The IGF-1 
to GH1 ratio of hormone concentrations was about 
25 times higher and did not show higher differences in 
full-term and prematurely born neonates. These results 
enable us to suggest that PGH is an important modula-
tor that maintains proper IGF-1 concentrations, and its 
secretion is not pulse. Chellakooty et al. [18] performed 
several examinations during pregnancy and showed 
a positive correlation between PGH concentration and 
foetal growth, as assessed by ultrasonography (USG). 
Our studies based on multivariate analysis indicate 
a positive correlation between neonate body mass and 
placenta mass in both investigated groups and also 
a correlation between full-term neonate body mass and 
IGF-1 concentration. In prematurely born infants, the 
correlation between PGH and IGF-1 concentrations was 
negative (Table IV). The results presented here and our 
suggestions require further investigations on a larger 
study group.
In terms of ghrelin concentrations, we have not 
shown statistically significant differences between 
full-term and prematurely born neonates, though in 
individual cases ghrelin concentrations were consid-
erably higher in small neonates. Some authors have 
observed significantly higher concentration values 
for ghrelin in small neonates, but most researchers 
have not found any statistically significant differences 
[19–22]. Our previous research on human foetuses 
demonstrated that stimulation of GH1 secretion by 
ghrelin is independent of the feedback control and 
these two hormones act as a metabolic balance signal 
[3, 23]. In adults, the hypothalamic pituitary axis regu-
lates pulse secretion of GH1 from the pituitary gland, 
but in foetuses is not functionally mature before the 
third trimester of pregnancy, independent of earlier 
anatomical differentiation [3].
The very high concentration of PGH in amniotic 
fluid, about tenfold higher than in umbilical cord blood, 
is surprising. Perhaps PGH undergoes partial degrada-
tion in umbilical cord blood caused by the different time 
of delivery and there could be a problem with the col-
lection of purified serum connected with this delivery. 
On the other hand, when comparing our results to the 
results of other researchers, the PGH concentrations in 
umbilical cord blood and amniotic fluid obtained by us 
are over three times higher. Sifakis et al. [10] observed 
high PGH concentrations in amniotic fluid in Down’s 
syndrome pregnancies.
There is still no answer to the question as to how 
PGH, which is secreted by the syncytiotrophoblast, 
penetrates into the foetal circulation and amniotic 
fluid. A question arises as to whether the synthesis of 
this hormone also takes place in foetal cells. Finally, 
the recognition of the role of PGH in a foetal organism 
requires further thorough studies on a larger scale.
Conclusion
Our research indicates both an important role for PGH 
in maintaining the proper IGF-1 pool, and a direct 
influence on placenta functions through the activa-
tion of compensation mechanisms, which stimulate 
IGF-1 synthesis. The role of PGH in postnatal life, and 
its concentrations, particularly in the first months of 
life, is yet to be clarified. In the mother’s organism this 
hormone undergoes a complete degradation after birth, 
and its fate in neonate blood is unknown. The trace 
concentration of IGF-1 in umbilical cord blood serum 
of five neonates, of whom three weighed less than 2,000 
g, is also unclear. Molecular studies in this area will be 
conducted in the future.
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